Ban on kidney cancer drugs lifted guardian.co.uk, UK - Nov 29, 2008 A ban on drugs that can give kidney cancer patients many months of extra life is to be lifted. At least two, and possibly all four, of the medicines that ...
NICE to green-light costly kidney meds FiercePharma, DC - According to NICE's calculations, the drugs were too costly for the additional survival time kidney cancer patients tended to experience when using them. ...
Health calendar Monroe News Star, LA - Family and Friends of Cancer Patients/Survivors ? Sponsored by the Louisiana Cancer Foundation, 6 pm third Tuesday of every month, Northeast Louisiana ...
Making aspirin work; standing up to lung cancer 6abc.com, PA - Nov 30, 2008 Lung cancer kills more Americans than breast, prostate, colon, liver, kidney and skin cancers combined. Ambrose says, "We've got to step back, ...
Ryanair shares plunge on profit warning MarketWatch - Jul 28, 2008 Also in 2006, Ryanair apologised after refusing to provide a sick cancer sufferer with a wheelchair. In 2007, Ryanair apologised after forcing a 14-year old ...RYAAY
GTx, Inc. Reports Second Quarter 2008 Financial Results StreetInsider.com (subscription), MI - Aug 5, 2008 As for our SARM collaboration with Merck, multiple Phase I and II clinical trials for the treatment of sarcopenia and cancer cachexia are ongoing. ...GTXI
BRUSSELS (Thomson Financial) - Market data at 12:43 pm Hemscott, UK - Jul 15, 2008 -Arseus up 0.04 euros or 0.50 percent at 8.00; sales rose to 90.4 million euros in the second quarter from 74.7 million a year earlier, above the 86-88 ...
Fannie and Freddie find fed funds: Micro-cap Monday Stockhouse, Canada - Jul 14, 2008 Even if we discounted revenue to $60 million and said it was only worth 0.50 times annual revenue, the business should still be worth $30 million. ...LEH - FNM - FRE
Quality of Life of Women with Ovarian Cancer - AB KORNBLITH, HT THALER, G WONG, V VLAMIS, J … - Gynecologic Oncology, 1995 - Elsevier ... OVARIAN CANCER PATIENTS? QUALITY OF LIFE ... Karnofsky a 0 0.44? 0 0.50? 0 0.55? 0 0.25**
0.55? 0.61? 0.24 ... (151) (148) (147) (146) (139) (138) (137) (140 ...
Vegetables, fruit, and lung cancer in the Iowa Women's Health Study - KA Steinmetz - Cancer Research, 1993 - AACR ... a nested case-control comparison of 138 cases with ... 0.49 (95% confidence interval,
0.28-0.86), 0.50 (95% confidence ... A lower lung cancer risk was also seen for ...
Source: Google Scholar
A subset of kidney cancer patients responds well to an experimental drug CCI-779
Researchers at UCLA ( University of California - Los Angeles ) knew - based on two clinical trials - that a subset of kidney cancer patients responded well to an experimental targeted therapy, but they didn't know why.
If they could determine the mechanism behind the response, they would be able to predict which patients would respond and personalize their treatment.
Extrapolating from the clinical responses, researchers at the Jonsson Cancer Center uncovered the cascade of molecular events by which the cancer cells in a subset of patients became sensitized to the experimental drug CCI-779. Armed with this information, UCLA researchers are developing a test to identify which patients will benefit from receiving CCI-779.
The research, published in the Nature Medicine, takes researchers a step closer to personalized medicine - treating cancer patients not with a one-size-fits-all therapy but with a treatment based on the specific molecular signature of their cancer cells.
" We knew there were certain kidney cancer patients who responded to this drug, but we didn't know the mechanism behind the response," said George Thomas, first author of the study. " We had to determine the mechanism of response so we could identify the responders."
Thomas, with Jonsson Cancer Center researchers Ingo Mellinghoff and Charles Sawyers, discovered that human kidney cancer cells that had lost the tumor suppressor gene Von Hippel Lindau ( VHL ) were more sensitive to the growth inhibitory effects of CCI-779.
One of the main functions of VHL is to regulate a protein called hypoxia inducible factor ( HIF ). When patients lost VHL, they had high levels of HIF. Thomas said the cancer cells became dependent on HIF to grow, so high levels of the protein gave the cancer cells a growth advantage.
CCI-779 had previously been tested at UCLA in prostate cancer patients and researchers knew it targeted the mTOR protein. Previous studies also had shown that inhibitors of mTOR also might inhibit HIF.
" We theorized that by inhibiting mTOR, which contributes to HIF levels, we might be able to significantly reduce HIF and remove the growth advantage the cancer cells had," Thomas said. " Because we now know the mechanism that is fueling the growth of the cancer cells, we can identify patients who will respond to this drug."
About 50 to 70 percent of kidney cancer patients have lost VHL, Thomas said. Their tumors, therefore, will have high levels of HIF and likely will respond to the drug. This finding could potentially help about 20,000 kidney cancer patients every year.
In this case, CCI-779 was being tested at UCLA in a Phase I study on patients with a variety of advanced cancers. Researchers noted that patients with kidney cancer seemed to respond better to the drug than patients with other cancer types. That led to a Phase II study solely in kidney cancer patients. That study showed that a subset of patients had a complete response, while a high percentage experienced partial responses or had their disease stabilize, meaning it was no longer growing.
Thomas predicted that CCI-779 would probably be most effective when given in combination with other therapies because it "in kidney cancer, it stops the tumor cells from growing, it doesn't kill them." It could be paired with conventional chemotherapy or with another targeted therapy, such as an angiogenesis inhibitor, which cuts off the independent blood supply that cancers need to grow and flourish. The CCI-779 would stop the growth of the cancer, and the chemotherapy would be used to kill the cancer cells or the angiogenesis inhibitor could be administered to cut off the blood supply to the tumor, stopping the flow of oxygen and nutrients that the tumor needs to survive.
Standard of care for kidney cancer is almost always removal of part or the entire kidney, so that tissue could be tested for the molecular signature that indicates response to CCI-779. Doctors could then decide on what treatment to use in those likely to respond to the drug.
A secondary study finding determined that the drug's efficacy can be monitored quickly using positron emission tomography ( PET ). Because HIF also regulates glucose transport in cells, UCLA researchers theorized that the kidney cancer cells, with their high levels of HIF, would take in a standard PET imaging probe at high levels. If that proved true, the PET scan would show that the cancer cells had increased levels of the probe. Using laboratory animals, researchers determined that kidney cancer cells were indeed better at taking up the probe, allowing the cancer cells to be monitored by PET scanning. Just 24 hours after treatment with CCI-779, intake of the PET probe levels dropped in the cancer cells, meaning HIF levels were falling and the drug was working.
" If we can use PET scanning to follow response, patients won't need repeated invasive tests," Thomas said. " This would save them from getting an added surgical procedure. And we can see, in a very short time, probably in less than a week, whether the drug is working."
Source: University of California - Los Angeles, 2006
